What is HC Wainwright’s Estimate for Absci Q1 Earnings?

Absci Co. (NASDAQ:ABSI) – Equities research analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Absci in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.27) per share for the quarter, down from their prior forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Absci’s current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci’s Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at ($0.02) EPS.

Absci (NASDAQ:ABSI) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03). Absci had a negative net margin of 2,321.56% and a negative return on equity of 46.56%. The firm had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $1.77 million.

Other analysts have also issued research reports about the company. Needham & Company LLC reissued a “buy” rating and issued a $9.00 target price on shares of Absci in a research report on Wednesday. Guggenheim reiterated a “buy” rating and issued a $10.00 price target on shares of Absci in a research note on Thursday. Finally, KeyCorp dropped their price objective on Absci from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.57.

Absci Trading Up 2.0 %

NASDAQ ABSI opened at $3.04 on Friday. The firm’s 50-day moving average is $3.86 and its two-hundred day moving average is $3.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. Absci has a 12 month low of $2.45 and a 12 month high of $6.72. The stock has a market capitalization of $349.16 million, a P/E ratio of -3.27 and a beta of 2.09.

Institutional Investors Weigh In On Absci

Hedge funds have recently added to or reduced their stakes in the company. PCA Investment Advisory Services Inc. acquired a new position in Absci during the fourth quarter worth $26,000. Alpha Cubed Investments LLC acquired a new position in shares of Absci during the 4th quarter worth $26,000. Ballentine Partners LLC purchased a new position in shares of Absci in the 4th quarter valued at about $27,000. BNP Paribas Financial Markets purchased a new stake in Absci during the fourth quarter worth about $28,000. Finally, Verdence Capital Advisors LLC acquired a new position in Absci during the fourth quarter worth about $37,000. Institutional investors and hedge funds own 52.05% of the company’s stock.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.